Cargando…
Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism by which antitumor antibodies mediate therapeutic efficacy. At present, we evaluate an Fc-optimized (amino acid substitutions S239D/I332E) FLT3 antibody termed 4G8-SDIEM (FLYSYN) in patients with acute myeloid leukemia (NCT02789254...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966676/ https://www.ncbi.nlm.nih.gov/pubmed/31817795 http://dx.doi.org/10.3390/cancers11121966 |
_version_ | 1783488791656267776 |
---|---|
author | Schmied, Bastian J. Lutz, Martina S. Riegg, Fabian Zekri, Latifa Heitmann, Jonas S. Bühring, Hans-Jörg Jung, Gundram Salih, Helmut R. |
author_facet | Schmied, Bastian J. Lutz, Martina S. Riegg, Fabian Zekri, Latifa Heitmann, Jonas S. Bühring, Hans-Jörg Jung, Gundram Salih, Helmut R. |
author_sort | Schmied, Bastian J. |
collection | PubMed |
description | Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism by which antitumor antibodies mediate therapeutic efficacy. At present, we evaluate an Fc-optimized (amino acid substitutions S239D/I332E) FLT3 antibody termed 4G8-SDIEM (FLYSYN) in patients with acute myeloid leukemia (NCT02789254). Here we studied the possibility to induce NK cell ADCC against B-cell acute lymphoblastic leukemia (B-ALL) by Fc-optimized FLT3 antibody treatment. Flow cytometric analysis confirmed that FLT3 is widely expressed on B-ALL cell lines and leukemic cells of B-ALL patients. FLT3 expression did not correlate with that of CD20, which is targeted by Rituximab, a therapeutic monoclonal antibody (mAb) employed in B-ALL treatment regimens. Our FLT3 mAb with enhanced affinity to the Fc receptor CD16a termed 4G8-SDIE potently induced NK cell reactivity against FLT3-transfectants, the B-ALL cell line SEM and primary leukemic cells of adult B-ALL patients in a target-antigen dependent manner as revealed by analyses of NK cell activation and degranulation. This was mirrored by potent 4G8-SDIE mediated NK cell ADCC in experiments with FLT3-transfectants, the cell line SEM and primary cells as target cells. Taken together, the findings presented in this study provide evidence that 4G8-SDIE may be a promising agent for the treatment of B-ALL, particularly in CD20-negative cases. |
format | Online Article Text |
id | pubmed-6966676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69666762020-02-04 Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody Schmied, Bastian J. Lutz, Martina S. Riegg, Fabian Zekri, Latifa Heitmann, Jonas S. Bühring, Hans-Jörg Jung, Gundram Salih, Helmut R. Cancers (Basel) Article Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism by which antitumor antibodies mediate therapeutic efficacy. At present, we evaluate an Fc-optimized (amino acid substitutions S239D/I332E) FLT3 antibody termed 4G8-SDIEM (FLYSYN) in patients with acute myeloid leukemia (NCT02789254). Here we studied the possibility to induce NK cell ADCC against B-cell acute lymphoblastic leukemia (B-ALL) by Fc-optimized FLT3 antibody treatment. Flow cytometric analysis confirmed that FLT3 is widely expressed on B-ALL cell lines and leukemic cells of B-ALL patients. FLT3 expression did not correlate with that of CD20, which is targeted by Rituximab, a therapeutic monoclonal antibody (mAb) employed in B-ALL treatment regimens. Our FLT3 mAb with enhanced affinity to the Fc receptor CD16a termed 4G8-SDIE potently induced NK cell reactivity against FLT3-transfectants, the B-ALL cell line SEM and primary leukemic cells of adult B-ALL patients in a target-antigen dependent manner as revealed by analyses of NK cell activation and degranulation. This was mirrored by potent 4G8-SDIE mediated NK cell ADCC in experiments with FLT3-transfectants, the cell line SEM and primary cells as target cells. Taken together, the findings presented in this study provide evidence that 4G8-SDIE may be a promising agent for the treatment of B-ALL, particularly in CD20-negative cases. MDPI 2019-12-06 /pmc/articles/PMC6966676/ /pubmed/31817795 http://dx.doi.org/10.3390/cancers11121966 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schmied, Bastian J. Lutz, Martina S. Riegg, Fabian Zekri, Latifa Heitmann, Jonas S. Bühring, Hans-Jörg Jung, Gundram Salih, Helmut R. Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody |
title | Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody |
title_full | Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody |
title_fullStr | Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody |
title_full_unstemmed | Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody |
title_short | Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody |
title_sort | induction of nk cell reactivity against b-cell acute lymphoblastic leukemia by an fc-optimized flt3 antibody |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966676/ https://www.ncbi.nlm.nih.gov/pubmed/31817795 http://dx.doi.org/10.3390/cancers11121966 |
work_keys_str_mv | AT schmiedbastianj inductionofnkcellreactivityagainstbcellacutelymphoblasticleukemiabyanfcoptimizedflt3antibody AT lutzmartinas inductionofnkcellreactivityagainstbcellacutelymphoblasticleukemiabyanfcoptimizedflt3antibody AT rieggfabian inductionofnkcellreactivityagainstbcellacutelymphoblasticleukemiabyanfcoptimizedflt3antibody AT zekrilatifa inductionofnkcellreactivityagainstbcellacutelymphoblasticleukemiabyanfcoptimizedflt3antibody AT heitmannjonass inductionofnkcellreactivityagainstbcellacutelymphoblasticleukemiabyanfcoptimizedflt3antibody AT buhringhansjorg inductionofnkcellreactivityagainstbcellacutelymphoblasticleukemiabyanfcoptimizedflt3antibody AT junggundram inductionofnkcellreactivityagainstbcellacutelymphoblasticleukemiabyanfcoptimizedflt3antibody AT salihhelmutr inductionofnkcellreactivityagainstbcellacutelymphoblasticleukemiabyanfcoptimizedflt3antibody |